Table 3.
Univariate proportional-hazards regression analysis of cofactors on progression-free survival in glioblastoma patients with conventionally fractionated radiotherapy.
| Cofactors | HR | 95% CI | p value |
|---|---|---|---|
| Karnofsky performance status > 80 | 1.16 | 0.68–1.96 | 0.59 |
| Peripheral versus central | 0.85 | 0.51–1.39 | 0.51 |
| MGMT promoter methylation | 0.93 | 0.68–1.34 | 0.60 |
| Biopsy versus surgical resection | 0.48 | 0.22–1.03 | 0.06 |
| Gross total resection versus subtotal resection | 0.70 | 0.41–1.40 | 0.38 |
| Temozolomide therapy | 0.60 | 0.32–1.09 | 0.09 |
| Mean IL ventricle dose ≥ 40 Gy | 0.56 | 0.32–0.98 | 0.043 |
| Mean CL ventricle dose ≥ 40 Gy | 0.61 | 0.26–1.44 | 0.26 |
| Mean IL SVZ dose ≥ 40 Gy | 0.40 | 0.24–0.78 | 0.002 |
| Mean CL SVZ dose ≥ 30 Gy | 0.44 | 0.21–0.92 | 0.030 |
| Mean IL DG dose ≥ 40 Gy | 1.42 | 0.81–2.51 | 0.22 |
| Mean CL DG dose ≥ 30 Gy | 0.86 | 0.31–2.40 | 0.77 |
CI: confidence interval; HR: hazard ratio; IL: ipsilateral; CL: contralateral; SVZ: subventricular zone; DG: dentate gyrus; Gy: gray; MGMT: O-6-methylguanine methyltransferase; RT: radiation therapy.